Humira receives FDA approval for moderate to severe psoriasis

Abbott today announced that Humira (adalimumab), which is already approved for psoriatic arthritis, rheumatoid arthritis, and other diseases, has been approved by the US Food and Drug Administration (FDA) to treat moderate to severe plaque psoriasis.

In a pivotal US and Canadian trial, at week 16 of treatment, 71% of psoriasis patients receiving Humira had achieved a 75% improvement in psoriasis symptoms (compared to 7% of patients receiving a placebo). Impressive figures.

FDA approval of this powerful new treatment option is good news for psoriasis patients.

[Further information: Introduction to Humira and other biologics.]